We examined how Saccharomyces boulardii might help with atopic dermatitis (AD), a challenging allergic condition. In a study with mice, S. boulardii was given either before or during the induction of AD-like symptoms.
This probiotic treatment showed promising results, reducing inflammation, improving skin and colon health, and lowering certain harmful blood markers. The study highlighted how S. boulardii can modulate inflammatory responses, suggesting it might be a useful support therapy for managing AD symptoms.
Read More
We explored the impact of combining Saccharomyces boulardii with cetirizine hydrochloride in treating allergic rhinitis in children. In a study involving 90 children, we divided them into two groups: one received only cetirizine, while the other was given both medications.
After four weeks, results showed that the group using Saccharomyces boulardii experienced a significantly higher rate of symptom improvement and better changes in immune markers compared to the control group. The combined treatment had an impressive 91.11% effectiveness rate compared to 68.89% for cetirizine alone, suggesting that this probiotic may enhance allergy management for children.
Read More
Potential asthma management via yeastPerinatal administration of Saccharomyces cerevisiae UFMG A-905 prevents asthma development in the offspring of mice.
Moderate relevance to asthma prevention
We explored how perinatal administration of Saccharomyces cerevisiae UFMG A-905 could help prevent asthma in mouse offspring. This study involved various groups of mice receiving the yeast at different stages: before conception, during pregnancy, or only during lactation.
Our results showed that those exposed to S. cerevisiae exhibited significantly less airway hyperresponsiveness and lower levels of certain inflammatory markers compared to those that didn’t receive the treatment. Notably, the greatest protection occurred when the yeast was given during lactation.
Overall, it seems that S. cerevisiae UFMG A-905 shows promise in the management of asthma, especially when administered early in the offspring's development.
Read More
Probiotic aids allergic asthma managementSaccharomyces boulardii alleviates allergic asthma by restoring gut microbiota and metabolic homeostasis via up-regulation of METTL3 in an m6A-dependent manner.
High relevance to asthma treatment
We explored the effects of Saccharomyces boulardii on allergic asthma in a mouse model. The study revealed that S. boulardii improved inflammation and lung damage, while also restoring gut microbiota and metabolic balance.
By analyzing gut microbiota and metabolites, we found that S. boulardii up-regulated METTL3, playing a key role in alleviating symptoms. This suggests that probiotics like S. boulardii could offer new strategies to tackle allergic asthma through healthier gut dynamics.
Read More
We explored how a symbiotic preparation with S. boulardii lysate affects gut permeability linked to allergies. In our study with Sprague Dawley rats, stress led to increased gut permeability and significant changes in intestinal structure. However, this stress-induced damage was partly counteracted by the KC-1317 preparation. Although the treatment helped maintain some intestinal health markers, it did not fully restore the altered gut hormone levels caused by stress. Overall, while some benefits were observed, the impact of S. boulardii on allergy-related gut issues remains limited.
Read More